SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (9719)12/10/2003 9:52:00 PM
From: Biomaven  Respond to of 52153
 
I believe the non eligibility of the over 50's is based not on any adverse events, but simply that that population was not evaluated.

In fact my recollection is that there were a number of older people in the Flumist trials, just not enough for a subgroup analysis to show efficacy. I also seem to recall that the traditional flu vaccine has never had an efficacy trial in older groups either.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News